The expression and clinical significance of immune checkpoints in acute myeloid leukemia
10.3760/cma.j.issn.1008-1372.2019.08.018
- VernacularTitle:不同免疫检查点基因在急性髓细胞白血病中的表达与临床意义
- Author:
Na CHENG
1
;
Lingzhang TIAN
;
Wei LIU
Author Information
1. 河南省儿童医院血液肿瘤科
- Keywords:
Leukemia,myeloid,acute;
Immunotherapy;
Genes,cell cycle checkpoints;
Molecular targeted therapy;
Computational biology
- From:
Journal of Chinese Physician
2019;21(8):1185-1189
- CountryChina
- Language:Chinese
-
Abstract:
Objective To find potential effective immunotherapy targets for acute myeloid leukemia (AML) by analyzing the expression and clinical significance of different immune checkpoints.Methods Gene expression profiles of AML cell lines (GSE57083) and tissues (GSE37642) were downloaded from GEO database.Then different immune checkpoints expression and clinical significance were analyzed with R studio and GraphPad software.Results In 16 AML cell lines,the expression rank of 11 immune checkpoints genes was LGALS9,PVRL2,PVR,PDCD1,TIM3,CTLA4,PDL1,GITR,LAG3,PDL2,GITRL,and among which LGALS9,PVRL2,GITR had larger variation between different cells.In AML tissues,the expression rank of immune checkpoint was LGALS9,PVRL2,TIM3,PDCD1,CTLA4,LAG3,GITR,PDL1,PVR,GITRL,PDL2.Survival analysis revealed high expression of PVR and LGALS9 was associated with poor prognosis,while the survival time had no significant difference in other genes.Conclusions PVR is highly expressed in AML tumor cells,and LGALS9 is highly expressed in both AML tumor cells and tissues.High expression of PVR and LGALS9 is associated with poor prognosis of AML patients,which may be a potential effective immunotherapy target for AML.
